Additional Chromosomal Abnormalities in Chronic Myeloid Leukemia Patient Treated with First-Line Tyrosine Kinase Inhibitor Therapy: Good or Poor Prognosis?
A 33-year-old male came to Policlinic of Hematology-Medical Oncology Dr. Cipto Mangunkusumo General Hospital for routine control of chronic myeloid leukemia (CML) treatment. He was treated with Imatinib Mesylate (IM) for two years. At the beginning of therapy, he showed good treatment response. Howe...
Main Authors: | Wulyo Rajabto, Noviana Joenputri |
---|---|
Format: | Article |
Language: | English |
Published: |
Interna Publishing
2022-12-01
|
Series: | Acta Medica Indonesiana |
Subjects: | |
Online Access: | https://actamedindones.org/index.php/ijim/article/view/1272 |
Similar Items
-
Influence of different chromosomal abnormalities in Ph-positive bone marrow cells on the chronic myeloid leukemia course during tyrosine kinase inhibitors therapy
by: O. Yu. Vinogradova, et al.
Published: (2014-07-01) -
Influence of different chromosomal abnormalities in Ph-positive bone marrow cells on the chronic myeloid leukemia course during tyrosine kinase inhibitors therapy
by: O. Yu. Vinogradova, et al.
Published: (2014-07-01) -
Second-Line Therapy Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myeloid Leukemia Resistant to Imatinib
by: Chici Pratiwi, et al.
Published: (2022-12-01) -
Peculiar age distribution of cytogenetic abnormalities in acute myeloid leukemia
by: E. W. Fleischman, et al.
Published: (2022-11-01) -
Conventional Cytogenetic and Molecular Analysis in Acute Myeloid Leukemia (AML) and Their Association with Overall Survival
by: Shakeri S., et al.
Published: (2021-11-01)